Foster City-based Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, is making strides in the development of small-molecule single-agent and combination therapies to tackle oncology, non-alcoholic steatohepatitis (NASH), and obesity. Among its pipeline of potential treatments is TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) designed to address chronic myeloid leukemia (CML), a cancer originating in bone marrow. The firm is also advancing TERN-501, a thyroid hormone receptor beta agonist aimed at enhancing liver distribution and metabolic stability for treatment of NASH, currently in a Phase IIa clinical trial. Finally, TERN-601, a Glucagon-Like Peptide-1 receptor agonist program intended for oral administration to tackle NASH and metabolic diseases such as obesity, is under development. Founded in 2016, Terns Pharmaceuticals is a notable player in the biopharmaceutical industry.
Terns Pharmaceuticals's ticker is TERN
The company's shares trade on the LSE stock exchange
They are based in London, England
There are 1-10 employees working at Terns Pharmaceuticals
It is ternspharma.com/leadership
Terns Pharmaceuticals is in the Technology sector